Alterations in long-term social behavior and gene expression were observed in the offspring of mice exposed to pain-killing opioids during pregnancy.
Newly synthesized compounds can halt the degradation of neurons in a range of neurodegenerative diseases, including Alzheimer's and Parkinson's disease, researchers say.
Trihexyphenidyl, an anticholinergic medication commonly prescribed for Parkinson's symptoms, appears to alleviate negative memory flashbacks and nightmares experienced by those with PTSD.
Two existing medications have been repurposed to treat sleep apnea. Researchers report the medications reduce symptoms of sleep apnea by 30%.
Gantenerumab, an investigational drug for Alzheimer's disease, reduced amyloid plaques and lowered tau levels in the brains of people with genetic risk factors for the neurodegenerative disorder.
A newly developed cannabidiol capsule can be absorbed by the body faster and penetrate the brain more quickly in mouse models of neurological disorders such as Alzheimer's disease, multiple sclerosis and TBI.
Elderly monkeys treated with CpG ODN had 59% fewer deposits of Alzheimer's related plaques in their brains compared to those who did not receive the treatment. The treatment also helped improve cognitive function and slow the progression of Alzheimer's symptoms.
Blocking substance P following a head injury can prevent tau protein tangles from forming in the brain and lower the risk for CTE and other head injury associated dementias.
Aduhelm, a new drug that appears to reduce amyloid plaques in the brain, is the first new Alzheimer's disease medication to be approved since 2003, and is the first drug that targets the fundamental pathology of the disease.